



(51) International Patent Classification:

A61K 38/16 (2006.01) A61P 19/02 (2006.01)
A61K 38/39 (2006.01) A61P 37/06 (2006.01)

(21) International Application Number:

PCT/US2024/021716

(22) International Filing Date:

27 March 2024 (27.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/492,715	28 March 2023 (28.03.2023)	US
63/504,003	24 May 2023 (24.05.2023)	US
63/584,134	20 September 2023 (20.09.2023)	US
63/624,959	25 January 2024 (25.01.2024)	US

(71) Applicant: **VIELA BIO, INC.** [US/US]; 1 Horizon Way, Deerfield, Illinois 60015 (US).

(72) Inventors: **ALEVIZOS, Ilias**; c/o Viela Bio, Inc., 1 Horizon Way, Deerfield, Illinois 60015 (US). **ILLEI, Gabor G.**; c/o Viela Bio, Inc., 1 Horizon Way, Deerfield, Illinois 60015 (US). **XIN, Yan**; c/o Viela Bio, Inc., 1 Horizon Way, Deerfield, Illinois 60015 (US). **REES, William A.**; c/o Viela Bio, Inc., 1 Horizon Way, Deerfield, Illinois 60015 (US).

MURRAY, Donna; c/o Viela Bio, Inc., 1 Horizon Way, Deerfield, Illinois 60015 (US). **DER, Kenneth R.**; c/o Viela Bio, Inc., 1 Horizon Way, Deerfield, Illinois 60015 (US). **WANG, Liangwei**; c/o Viela Bio, Inc., 1 Horizon Way, Deerfield, Illinois 60015 (US).

(74) Agent: **HEENAN, Erin et al.**; c/o Amgen Inc., One Amgen Center Drive, Legal Dept-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: CD40L-SPECIFIC TN3-DERIVED SCAFFOLDS FOR THE TREATMENT AND PREVENTION OF SJOGREN'S SYNDROME




FIG.1

(57) Abstract: Provided are compositions and methods comprising a CD40L-specific Tn3 scaffold. Also provided are methods of utilizing the same for the prevention and treatment of Sjögren's Syndrome.

[Continued on next page]

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*